Synaptogenix Inc (SNPX)

[SF Wolf]

Essentially a re-write of the NPR piece "After A Big Failure, Scientists And Patients Hunt For A New Type Of Alzheimer's Drug".

As we get closer to Top Line results I would expect many more articles about Neurotrope and Byrostatin.

Seeing an update by Maxim Group, or a larger firm initiating coverage would be helpful.

The Alzheimer's Solution Conference, where Dr. Alkon will be one of the featured speakers, has a broad audience of researchers, physicians, funders, and patient families and will hopefully generate additional interest.